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Objective: to examine the effect of angiotensin converting enzyme inhibition (ACEI) on soluble intercellular adhesion
molecule 1 (sICAM-1) and C-reactive protein (CRP) in patients requiring coronary artery bypass grafting (CABG).
Method: subgroup analysis of 42 patients randomised to Quinapril (40 mg daily determined) and 45 to placebo. sICAM-1
and CRP were $4 weeks before and 1 year after surgery.
Results: there was no difference in sICAM-1 at baseline (142.2 mg/L vs 136.6 mg/L). There was significant reduction in s-
ICAM-1 in patients receiving quinapril (142.2 ^ 10.8 mg/L vs 125.6 ^ 9.4 mg/L, p , 0.05) but not placebo
(136.6 ^ 10.2 mg/L vs 131.2 ^ 11.7 mg/L, p ¼ NS). Levels of C-reactive protein remained unchanged in both groups
(3.70 ^ 0.85 vs 2.73 ^ 0.32 mg/L, 2.85 ^ 0.48 vs 3.16 ^ 0.50 mg/L).
Conclusions: ACEI reduces sICAM-1 in patients undergoing CABG. The benefits of ACEI may partly be due to a reduction
of the vascular inflammatory response.
Key Words: Angiotensin-converting-enzyme-inhibitor; Inflammation; Atherosclerosis; Coronary heart disease; Cell
adhesion molecules; C-reactive protein.
Introduction
Angiotensin-converting-enzyme (ACE)-inhibitors
reduce morbidity and mortality in patients athero-
sclerotic vascular disease1 through their haemody-
namic effects and, possibly, though beneficial effects on
the endothelium. In vitro studies suggest these might
include a reduction in cellular adhesion molecule
(CAM) expression2 – 7 and leucocyte adhesion.8,9 Sol-
uble CAM levels are elevated in patients with
atherosclerosis10 – 12 but, to date, the effects of ACE-
inhibitors on these levels is unknown. The aim of this
study was to determine the effect of ACE-inhibition on
levels of soluble intercellular adhesion molecule 1
(sICAM-1) and C-reactive protein (CRP) in patients
undergoing coronary artery bypass grafting (CABG).
Materials and Methods
The current study was performed in a subgroup of 87
patients from the randomised, double-blind, placebo-
controlled QUO VADIS trial that was designed to
evaluate the effect of ACE-inhibition (Quinapril 40 mg
once daily) on ischaemic events up to 1 year post-
CABG.13,14 This subgroup was solely defined by the
availability of a stored (at 280 8C) blood sample taken
$4 weeks before and 1 year after surgery. Institutional
Review Board approval and written informed consent
were obtained. sICAM were determined using in-
house ELISA.15 CRP was measured using an ELISA
assay with a sensitivity of 20 ng/L.16 Both samples
were analyzed at the same time in duplicate. No other
measurements were performed. A p-value ,0.05 was
considered statistically significant. The baseline
descriptive statistics for the continuous variables are
mean and standard error of the mean. For normally
distributed continuous variables, differences between
quinapril and placebo were evaluated by a two-sided
Student’s T-test. For skewed distributed continuous
endpoints (p-value Shapiro–Wilk test for normality
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,0.05), a Wilcoxon 2-sample test was used. Qualitat-
ive parameters (categorical or ordered), frequency
counts and percentages of each category were
calculated by treatment group. Differences between
quinapril and placebo were then evaluated using a
Chi-square test. To evaluate the effect of quinapril
versus placebo on the change of levels of s-ICAM from
baseline to 1 year, a repeated measurement analysis of
variance was used. Clinically relevant co-variates with
a p-value,0.20 in univariate analysis were considered
as potential confounders and included in a multi-
variable model. To evaluate the change of s-ICAM
within the treatment subgroups, two additional
repeated measurement analyses of variance were
performed in the quinapril treated patients and
placebo treated patients separately. For additional
computations of correlations between s-ICAM and C-
reactive protein, the Spearman correlation coefficients,
with accompanying p-values were calculated
(Prob . R under Ho: Rho ¼ 0). For all analyses,
commercially available computer software (Statistical
Analysis System version 6.12, SAS Institute, Cary, NC,
U.S.A.) was used.
Results
Of the 87/149 randomised patients studied (Table 1),
45 received placebo and 42 quinapril. Despite the
small sample size the two groups were well matched
(Tables 2–4). sICAM did not differ significantly
between groups at baseline (136.6 ^ 10.2 mg/L vs
142.2 ^ 10.8 mg/L, p ¼ NS). However, in quinapril
group, levels significantly decreased from
Table 1. Baseline characteristics of included versus excluded patients.
Included ðn ¼ 87Þ Excluded ðn ¼ 62Þ p-value
Age (y) 63 (^0.9) 61 (^1.2) 0.52
Male ðnð%ÞÞ 75 (86) 51 (82) 0.65
Medical history ðnð%ÞÞ
Myocardial infarction 36 (41) 27 (44) 0.87
Cardiovascular intervention 11 (13) 9 (15) 0.81
Hypertension ðnð%ÞÞ
None 69 (79) 46 (74) 0.49
Past 3 (3) 1 (1)
Current 15 (17) 15 (24)
Diabetes mellitus ðnð%ÞÞ 9 (10) 0 (0) 0.01
Smoking ðnð%ÞÞ
None 15 (17) 11 (18) 0.1
Past 56 (64) 42 (76)
Current 16 (18) 4 (6)
Family history of cardiovascular disease ðnð%ÞÞ 38 (44) 26 (42) 0.87
Co-medication ðnð%ÞÞ
ASA 70 (80) 43 (69) 0.13
Coumarines 13 (15) 20 (32) 0.02
Beta-blockers 78 (90) 51 (83) 0.23
Calcium antagonists 66 (76) 42 (68) 0.35
Nitrates 66 (76) 54 (87) 0.1
Lipid lowering 36 (41) 20 (32) 0.3
Blood pressure (mmHg)
Systolic 143 (^1.9) 145 (^2.6) 0.66
Diastolic 84 (^1.0) 85 (^1.1) 0.94
Body mass index (kg/m2) 26 (^0.3) 27.5 (^0.4) 0.02
NYHA ðnð%ÞÞ
Class I 4 (5) 1 (1) 0.46
Class II 36 (42) 25 (40)
Class III 44 (51) 32 (52)
Class IV 1 (2) 4 (7)
Total cholesterol (mmol/L) 6.23 (^0.14) 6.25 (^0.15) 0.72
HDL-cholesterol (mmol/L) 1.02 (^0.03) 1.16 (^0.05) 0.01
LDL-cholesterol (mmol/L) 4.21 (^0.12) 4.30 (^0.13) 0.58
Triglycerides (mmol/L) 2.09 (^0.15) 1.88 (^0.15) 0.34
Data are expressed as means ^ standard error of the mean. nð%Þ equals the number of patients (percentage). A p-value less than 0.05 is
considered as clinically significant.
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142.2 ^ 10.8 to 125.6 ^ 9.4 mg/L ðp , 0:05Þ: There was
no such change in the placebo group (136.6 ^ 10.6 mg/L
vs 131.2 ^ 1.7 mg/L) (Fig. 1). To exclude a possible
confounding effect of obscure concomitant disease
such as infection or malignancy, the analysis was
repeated after excluding three patients with extremely
elevated (.3 SD above the mean) CRP. It did not alter
the outcome and all three patients were assigned
to placebo. Without these patients mean levels of
s-ICAM were 134.5 ^ 10.9 mg/L at baseline and
132.5 ^ 11.2 mg/L after one year (n ¼ 42; p ¼ NS).
CRP was similar in both groups at baseline and did
Table 2. Patient characteristics of the analyzed patients per treatment group at baseline.
Placebo ðn ¼ 45Þ Quinapril ðn ¼ 42Þ p-value
Age (y) 63 (^1.4) 62 (^1.2) 0.41
Male ðnð%ÞÞ 38 (84) 37 (88) 0.76
Medical history ðnð%ÞÞ
Myocardial infarction 16 (36) 20 (48) 0.28
Cardiovascular intervention 7 (16) 4 (10) 0.52
Hypertension ðnð%ÞÞ
None 35 (78) 34 (90) 0.86
Past 2 (4) 1 (2)
Current 8 (18) 7 (17)
Diabetes mellitus ðnð%ÞÞ 2 (4) 7 (17) 0.08*
Smoking ðnð%ÞÞ
None 9 (20) 6 (14) 0.66
Past 29 (64) 27 (64)
Current 7 (16) 9 (21)
Family history of cardiovascular disease ðnð%ÞÞ 14 (31) 24 (57) 0.02*
Co-medication ðnð%ÞÞ
ASA 34 (76) 36 (86) 0.29
Coumarines 7 (16) 6 (14) 1.00
Beta-blockers 45 (90) 38 (91) 1.00
Calcium antagonists 34 (76) 32 (76) 1.00
Nitrates 36 (80) 30 (71) 0.45
Lipid lowering 18 (40) 18 (43) 0.83
Blood pressure (mmHg)
Systolic 142 (^2.4) 145 (^3.0) 0.44
Diastolic 82 (^1.4) 85 (^1.3) 0.53
Body mass index (kg/m2) 26 (^0.5) 26 (^0.4) 0.86
NYHA ðnð%ÞÞ
Class I 2 (4) 2 (5) 0.38
Class II 15 (33) 21 (51)
Class III 27 (60) 17 (42)
Class IV 1 (2) 1 (2)
Total cholesterol (mmol/L) 6.01 (^0.16) 6.46 (^0.23) 0.19*
HDL-cholesterol (mmol/L) 1.04 (^0.04) 1.00 (^0.04) 0.83
LDL-cholesterol (mmol/L) 4.14 (^0.15) 4.28 (^0.19) 0.56
Triglycerides (mmol/L) 1.78 (^0.16) 2.42 (^0.26) 0.04*
Data are expressed as means ^ standard error of the mean. n equals the number of patients. A p-value less than 0.05 is considered as clinically
significant.
*Indicates variables that were tested in a multivariate model.
Table 3. Blood pressure and lipid levels at baseline and at the end of the study per treatment group.
Quinapril ðn ¼ 42Þ Placebo ðn ¼ 45Þ
Baseline End of study Baseline End of study
Blood pressure
Systolic (mmHg) 145 (^3.0) 151 (^2.9) 142 (^2.4) 150 (^3.3)
Diastolic (mmHg) 82 (^1.4) 84 (^1.6) 85 (^1.3) 85 (^1.4)
Total cholesterol (mmol/L) 6.5 (^1.5) 6.0 (^1.1) 6.0 (^1.1) 5.7 (^1.1)
Triglycerides (mmol/L) 2.4 (^1.7) 1.8 (^1.1) 1.78 (^1.1) 1.7 (^0.9)
Blood pressure and lipid levels are expressed as mean ^ standard error of the mean. n equals the number of patients.
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not change during the study period. In the quinapril
group levels were 3.70 ^ 0.85 mg/L at baseline vs
2.73 ^ 0.32 mg/L after 1 year (Fig. 2). In the placebo
group levels were 2.85 ^ 0.48 mg/L at baseline vs
3.16 ^ 0.50 mg/L after 1 year.
There was a weak correlation between CRP and s-
ICAM at baseline (r ¼ 0:30; p , 0:01) and after one
year (r ¼ 0:29; p , 0:01).
Discussion
The beneficial effects of ACE-inhibitors in left ven-
tricular hypertrophy and chronic heart failure17,18
were attributed mainly to the reduction of myocardial
remodelling. The benefits in atherosclerosis are
equally clear but harder to explain.1,8 The anti-
inflammatory effects of ACE-inhibition have been
previously demonstrated in patients with heart fail-
ure, other mechanisms than modification of the
atherosclerotic process may have accounted for the
results in these studies.19,20 The present study has
shown that 12 months of ACE-inhibition leads to a
significant reduction in sICAM-1 but not CRP in
patients who have undergone CABG. sICAM is a
powerful independent predictor of the risk of devel-
oping coronary heart disease.21 It is reasonable
assume, therefore, that a decrease in levels of s-
ICAM reflects a diminution of cardiovascular risk.
This assumption is currently investigated in the
BIological Markers of Endothelial Dysfunction
(BIMED) study is capable of inducing pro-inflamma-
tory cellular activity.22 – 25 It is present and active in the
most vulnerable parts of the atherosclerotic plaque26
and it elevates s-ICAM in humans.27 The reduction in
s-ICAM observed here can be explained by the fact
that quinapril reduces angiotensin II formation in
human vasculature.14 On the other hand, ACE-
inhibition improves endothelial function by increasing
the bioavailability of nitric oxide.28 Perhaps surpris-
ingly, treatment did not lead to a significant reduction
in CRP.21,29 – 33 This study does have limitations. The
patients were part of a larger cohort, selection bias
cannot be ruled out, the original study was not
primarily designed to study the effects of quinapril
on levels of s-ICAM and CRP, and the small sample
size did not permit the analysis of the link between s-
ICAM and the occurrence of clinical endpoints.
In conclusion, this study demonstrated for the first
time that a treatment with quinapril (40 mg once daily)
significantly reduces the s-ICAM levels in patients
with atherosclerosis requiring CABG. This supports
the contention that the beneficial effects of ACE-
inhibition are partly the result of a reduced vascular
inflammatory response. The larger BIMED trial is
currently underway and will hopefully verify this
hypothesis.
Table 4. Use of statins and salicylates (ASA) during the study per treatment group.
Treatment status Statins ðnð%ÞÞ ASA ðnð%ÞÞ
Quinapril n ¼ 42 Placebo n ¼ 45 Quinapril n ¼ 42 Placebo n ¼ 45
Never 17 (41) 21 (47) 2 (5) 4 (9)
Discontinued 1 (2) 1 (2) 8 (19) 4 (9)
Started during study 17 (41) 16 (36) 28 (66) 30 (67)
Already 7 (17) 7 (16) 4 (10) 7 (16)
Drug use is expressed as number of patients (percentage of the group); ASA means salicylates. n equals the number of patients.
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